Target intelligence / Profile preview

Tumor necrosis factor ligand superfamily member 15 (TL1A) (TL1A)

Target
TL1A
Molecular classification
Cytokine, Tumor necrosis factor superfamily
01

Overview

Tumor necrosis factor ligand superfamily member 15 (TNFSF15), commonly known as tumor necrosis factor-like ligand 1A (TL1A), is a multifunctional cytokine belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed by endothelial cells, macrophages, and dendritic cells, and acts as a potent costimulator of T cells and innate lymphoid cells by binding to its cognate receptor, death receptor 3 (DR3). This interaction activates downstream pro-inflammatory signaling pathways, such as NF-κB and MAPK, driving the secretion of inflammatory cytokines. Additionally, TL1A directly stimulates fibroblasts to promote collagen deposition and tissue remodeling, positioning it at the intersection of chronic inflammation and fibrotic pathways. Dysregulation and overexpression of TL1A are strongly implicated in the pathogenesis of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, as well as other autoimmune and fibrotic conditions like systemic sclerosis, rheumatoid arthritis, and psoriasis. Consequently, TL1A has emerged as a highly promising therapeutic target. Monoclonal antibodies targeting TL1A, such as tulisokibart, afimkibart, and duvakitug, are designed to neutralize both soluble and membrane-bound forms of the cytokine, thereby blocking the TL1A-DR3 signaling axis to alleviate tissue inflammation and reverse fibrotic changes.

Other names
Tumor necrosis factor-like ligand 1ATumor necrosis factor-like cytokine 1AVascular endothelial cell growth inhibitorVEGITNF ligand-related molecule 1TL1TNFSF15
02

Mechanism of action

Monoclonal antibody that binds to and neutralizes soluble and membrane-bound TL1A, preventing its interaction with death receptor 3 (DR3) and decoy receptor 3 (DcR3), thereby inhibiting downstream inflammatory and fibrotic signaling pathways.

03

Biological functions

Immune responseApoptosisSignal transductionCell proliferationAngiogenesis inhibitionT-cell costimulationFibrogenesis
04

Disease associations

Inflammatory bowel diseaseUlcerative colitisCrohn's diseaseSystemic sclerosisRheumatoid arthritisPsoriasisAsthmaCancer
05

Safety considerations

Infection risk (e.g., upper respiratory tract infection, nasopharyngitis, urinary tract infection)Immunogenicity (anti-drug antibodies)Exacerbation of colitisInfusion or injection site reactionsAnemiaFatigueHeadache
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

TNFSF15 genetic risk allelesSerum TL1A levelsMucosal TL1A expressionSerum proteomic markers (OSM, AREG, HGF, MMP8, MMP12)

Beyond the preview

Go deeper on Tumor necrosis factor ligand superfamily member 15 (TL1A) (TL1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 15 (TL1A) (TL1A).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call